紫光國微(002049.SZ):擬向中國進出口銀行北京分行申請額度不超6億元
格隆匯 11 月 1日丨紫光國微(002049.SZ)公佈,公司第七屆董事會第八次會議決議,審議通過《關於向銀行申請綜合授信額度的議案》。
同意公司根據實際經營的需要,向中國進出口銀行北京分行申請額度不超過6億元人民幣,期限為2年期的綜合授信,綜合授信內容包括但不限於流動資金貸款、保函、信用證、債投債承類、福費廷等。此次綜合授信擬由公司間接控股股東紫光集團有限公司提供無償擔保。
上述授信在額度內可分多次循環使用,授信額度內的具體融資金額將視公司的實際需求決定,以公司與銀行正式簽署的協議為準。
同意授權公司董事長全權代表公司簽署上述綜合授信的相關文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.